Chester County News and Community Website
WILMINGTON, DE — AstraZeneca received U.S. regulatory approval for BAXFENDY (baxdrostat), a new treatment for adults with uncontrolled hypertension, marking the first new drug class for the condition in years …
FDA Clears AstraZeneca Blood Pressure Drug, Expanding Options for Uncontrolled Hypertension Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said it expects to complete enrollment in its pivotal BACKBEAT clinical trial by the end of the third quarter of …
Orchestra BioMed Targets 2027 Data for Hypertension Trial Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $20 million investment from Medtronic plc (NYSE: MDT) tied to the companies’ ongoing collaboration to develop a pacemaker-based …
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial Read More
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported its fourth-quarter and full-year 2025 financial results and said the U.S. Food and Drug Administration has accepted its new drug application …
Mineralys Reports 2025 Results, Advances Hypertension Drug Review Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) said its Phase 3 Launch-HTN clinical trial evaluating lorundrostat was selected by JAMA editors as one of the most impactful medical studies …
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension Read More
WEST CONSHOHOCKEN, PA — PRM Pharma, LLC announced the nationwide launch of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for adult hypertension. …
PRM Pharma Launches First FDA-Approved 12.5 mg Chlorthalidone for Hypertension Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More
WILMINGTON, DE — New data from the BaxHTN Phase III trial indicate that baxdrostat, an investigational aldosterone synthase inhibitor, achieved significant reductions in systolic blood pressure among patients with uncontrolled …
Phase III Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Hard-to-Treat Hypertension Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced new data published in JACC: Clinical Electrophysiology demonstrating the potential of its atrioventricular interval modulation (AVIM) therapy to reduce …
Orchestra BioMed Publishes Data Supporting Blood Pressure Therapy in Hypertensive Pacemaker Patients Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More